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Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities,
and cutaneous and visceral fibrosis. Serum autoantibodies directed to multiple intracellular
antigens are present in more than 95% of patients and are considered a hallmark of SSc.
They are helpful biomarkers for the early diagnosis of SSc and are associated with distinc-
tive clinical manifestations. With the advent of more sensitive, multiplexed immunoassays,
new and old questions about the relevance of autoantibodies in SSc are emerging. In this
review, we discuss the clinical relevance of autoantibodies in SSc emphasizing the more
recently published data. Moreover, we will summarize recent advances regarding the sta-
bility of SSc autoantibodies over the course of disease, whether they are mutually exclusive
and their potential roles in the disease pathogenesis.
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INTRODUCTION
Systemic sclerosis (SSc) is a chronic autoimmune rheumatic dis-
ease (ARD) of unknown etiology characterized by microvascular
abnormalities, cutaneous and visceral fibrosis all accompanied by
signature immune abnormalities. Clinically, SSc is a heterogeneous
disease with a broad range of manifestations, including Raynaud’s
phenomenon, and cutaneous, gastrointestinal, renal, cardiovas-
cular, and pulmonary involvement. SSc patients are classified as
diffuse cutaneous SSc (dcSSc), characterized by widespread and
rapidly progressive skin thickening, and earlier and more severe
internal organ involvement, or limited cutaneous SSc (lcSSc) in
which skin thickening is restricted to the distal extremities and
face, and accompanied by less severe and later onset internal organ
involvement (1).
The presence of serum autoantibodies directed to multiple
intracellular antigens is a serological hallmark of SSc. In SSc,
these autoantibodies are present in more than 95% of patients
and are helpful biomarkers for establishing an early and accu-
rate diagnosis (2). It is intriguing that they are also associated
with distinctive clinical subsets, specific patterns of organ involve-
ment, and different prognostic features (3). Some of them are
considered highly specific for SSc, including anti-topoisomerase
1 (ATA), anti-centromere (CENP), and anti-RNA polymerase
III, and these were recently added to the 2013 American Col-
lege of Rheumatology/European League against Rheumatism
(ACR/EULAR) SSc classification criteria (4). In addition, several
other autoantibodies can be detected, which include anti-U3-
RNP/fibrillarin, anti-Th/To, and anti-RNA-polymerase I and II
that often produce a nucleolar staining by indirect immuno-
fluorescence (IIF), and anti-U11/U12 RNP (2). The sensitivity
and specificity of these autoantibodies varies in SSc cohorts
depending on the ethnicity and the geographic region of ori-
gin, immunogenetic markers, as well as the autoantigen and
immunoassay used (2, 5). Autoantibodies that are reported
in other ARD can also be present in SSc, including anti-
PM/Scl, anti-Ku, anti-U1-RNP, anti-SS-A/Ro60, and anti-NOR
90 (Table 1). More recently, some autoantibodies with possible
pathogenic properties, including anti-platelet-derived growth fac-
tor (PDGF) receptor antibodies, anti-endothelial cells antibodies
(AECA), anti-fibroblast, anti-angiotensin type 1 receptor (AT1R),
and endothelin-1 type A receptor (ETAR) (3, 6, 7), have been
described.
This review will focus on the clinical relevance of autoanti-
bodies in SSc with particular attention to recently published data.
Moreover, some unanswered questions will be discussed including
the stability of these antibodies over disease course, if SSc autoan-
tibodies are really mutually exclusive and their roles in the disease
pathogenesis.
AUTOANTIBODIES IN SSc
Anti-topoisomerase I antibodies (ATA) were initially named
anti-Scl-70 because they reacted with a 70 kDa protein on
immunoblots. It was later recognized that Scl-70 was a misnomer
because additional studies showed that this was a breakdown prod-
uct of the full-length 100 kDa protein. ATA have been reported in
15–42% of SSc patients, with a specificity ranging from 90 to 100%
(2, 8). ATA are strongly associated with dcSSc and a poor prog-
nosis. Nonetheless, ATA have also been reported in patients with
lcSSc and other ARD. SSc patients with ATA have a higher risk of
having severe pulmonary fibrosis and cardiac involvement. ATA
has been also associated with joint involvement, tendon friction
rubs, and presence of digital ulcers (2, 8, 9). The association with
renal crisis has been reported but not consistently found in all SSc
cohorts. Moreover, the presence of ATA in patients with Raynaud’s
phenomenon is predictive in that they are associated with a high
risk of developing of SSc (9).
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Table 1 | Frequency and clinical correlations of systemic sclerosis (SSc) autoantibodies.
% Frequency
in SSc
Disease subtype Clinical associations Prognosis
Anti-centromere 20–38 lcSSc Pulmonary arterial hypertension Better prognosis
Anti-topoisomerase I 15–42 dcSSc Pulmonary fibrosis Worse prognosis
Heart involvement
Anti-RNA polymerase III 5–31 dcSSc Renal crisis Increased mortality
Tendon friction rubs, synovitis, myositis, joint
contractures
Anti-U3RNP (fibrillarin) 4–10 dcSSc Renal crisis and cardiac involvement Poor prognosis especially
in African-Americans
Anti-Th/To 1–13 lcSSc Pulmonary fibrosis and renal crisis Poor prognosis
Anti–U11/U12 RNP 3.2 – Raynaud’s phenomenon Increased mortality
Gastrointestinal involvement
Lung fibrosis
Anti-U1-RNP 2–14 lcSSc Raynaud’s phenomenon, puffy fingers, arthritis,
myositis, overlap syndrome (i.e., MCTD)
Better prognosis
Anti-PM-Scl 4–11 Overlap with
polymyositis
Raynaud’s phenomenon, arthritis, myositis, pulmonary
involvement, calcinosis, and sicca symptoms
Better prognosis
lcSSc
Anti-Ku 2–4 – Myositis, arthritis, and joint contractures –
Anti-hUBF (NOR 90) <5 lcSSc Mild internal organ involvement Better prognosis
Anti-Ro52/TRIM21 15–20 Association with other
autoimmune diseases
Older age onset, pulmonary fibrosis –
dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc; MCTD, mixed connective tissue disease; RNP, ribonucleoprotein; TRIM, tripartite motif.
Anti-centromere antibodies (CENP) were first described in 1980
when tissue culture cells, such as HEp-2 cells, were replacing cry-
opreserved tissue sections as the substrate of choice for ANA
IIF testing. A number of CENP proteins (CENP-A, CENP-B,
CENP-C, and several others) have been described, but CENP-
B is thought to be the primary target of the B cell anti-CENP
response in SSc (2). Besides the detection by IIF on HEp-2
cells, ELISA, line immunoassay (LIA), and addressable laser bead
immunoassay (ALBIA) diagnostic platforms have been adopted
for the detection of anti-CENP (2, 8). There is general consen-
sus that anti-CENP is the most common autoantibody detected
in SSc cohorts with frequencies that range from 20 to 38% (2,
5, 10). Although anti-CENP are relatively specific for SSc, they
have also been reported in systemic lupus erythematosus (SLE),
primary biliary cirrhosis, Sjögren’s syndrome, and in patients
with Raynaud’s phenomenon. As with ATA, anti-CENP are highly
predictive of impending SSc in patients with Raynaud’s phe-
nomenon (2, 9). Anti-CENP is classically associated with lcSSc
and a better prognosis compared to other SSc-related antibodies.
Anti-CENP is also negatively associated with cardiac and renal
involvement. By contrast, anti-CENP is associated with a higher
risk of pulmonary arterial hypertension (PAH) and an attending
higher risk of mortality among this particular clinical subset of
patients (9).
Anti-RNA polymerase I, II, and III antibodies (anti-RNAP)
were first described in the early 1990s. Anti-RNAP I and III
antibodies almost always coexist and are considered highly spe-
cific for SSc (2). Anti-RNAP II antibodies are also found in
SLE and overlap syndrome, and are not as specific for SSc. The
nucleolar speckled IIF pattern typically associated with anti-
RNAP is not a sensitive method for the detection of these
autoantibodies, and ELISA and LIA are now commonly used
for their detection (2, 11). The frequency of anti-RNAP I and
III varies from 5 to 31% of SSc patients. In a recent meta-
analysis, the overall pooled prevalence of anti-RNAP III was
11% (11). RNAP autoantibodies are associated with dcSSc and
a higher risk for renal crisis. These patients might also have
a higher risk of tendon friction rubs, synovitis, myositis, joint
contractures, and risk of developing a malignancy. Despite the
prevalence of renal involvement, the survival rate in patients
with anti-RNAP is better than in patients with ATA or anti-
U3RNP (9).
Anti-fibrillarin (or anti-U3RNP) antibodies recognize a highly
conserved 34-kDa basic protein of the U3 small nucleolar
ribonucleoprotein (U3RNP) macromolecular complexes called
fibrillarin. They were initially associated with a clumpy nucle-
olar staining IIF pattern on HEp-2 cells but their presence
should be confirmed using complementary assays such as
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immunoprecipitation of radiolabeled proteins, specialized West-
ern blots, or LIA (2). Anti-U3RNP antibodies are detected in
4–10% of SSc patients, and are considered relatively specific for
SSc, and mutually exclusive from CENP, ATA, and anti-RNAP (2,
10). They are more frequently found in African-American patients
than in Caucasian or Asian SSc patients. Anti-U3RNP are asso-
ciated with dcSSc, frequent visceral involvement, and especially
renal and cardiac involvement. In African-American patients, anti-
fibrillarin antibodies are associated with severe pulmonary disease,
pulmonary hypertension, severe small bowel involvement, and a
poor prognosis (9).
Anti Th/To antibodies typically produce a homogenous nucle-
olar IIF staining pattern on HEp-2 substrates. Anti-Th/To anti-
bodies primarily bind to two proteins of the mitochondrial RNA
processing (MRP) and the ribonuclease P complexes. They are
present in 1–13% of SSc patients, are considered to be relatively
specific for SSc, are primarily associated with lcSSc, and a high
frequency of pulmonary fibrosis and scleroderma renal crisis and,
hence, a poor prognosis (9). Identification of clear-cut clinical
associations has been hampered to date by the limited availability
of immunoassays (8).
Anti-U11/U12 RNP antibodies have been described in 3.2%
of SSc patients. In a study by Fertig et al (12), anti-U11/U12 RNP
antibodies were associated with Raynaud’s phenomenon, gastroin-
testinal involvement, severe pulmonary fibrosis, and a higher risk
of mortality (12).
OTHER AUTOANTIBODIES
Other autoantibodies, including anti-U1-RNP, anti-PM-Scl, anti-
Ku, anti-Ro60/SS-A, anti-Ro52/TRIM21, and anti-NOR 90 tend
to be found in SSc-overlap syndromes as well as in other ARD, and
are considered less specific for SSc (Table 1) (2).
STABILITY OF AUTOANTIBODIES IN SSc OVER DISEASE
COURSE
The titers of most SSc-related autoantibodies are considered to
remain relatively stable over the course of the disease. Nonethe-
less, immunoassays that are able to reliably quantitate differences
in SSc autoantibody levels have recently become available. Hence,
studies evaluating the dynamics of autoantibody titers, or pro-
files over the protracted clinical course of SSc, or the impact of
treatment have yet to be validated in multi-center studies.
Using semi-quantitative immunoassays, early studies reported
that anti-CENP levels were relatively stable over long-term clinical
observation (8, 13). Although controversial, others studies have
indicated that increased levels of ATA were associated with the
development of serious organ involvement or more prominent
skin thickness (8, 14, 15). Interestingly, one study observed that
ATA became undetectable in 20% of ATA positive patients dur-
ing the disease course. These patients presented with less extensive
skin and lung involvement and better survival rates than patients
with persistently elevated ATA (15). This remarkable decrease in
ATA levels was accompanied by a reduction in isotype expres-
sion and epitope reactivity (15). An analysis of 212 SSc patients
who were ATA positive and had different skin thickness progres-
sion rates (STPRs) also showed a positive correlation between the
immunoglobulin G (IgG) ATA levels and the STPRs and the mod-
ified Rodnan skin thickness score, suggesting that serum levels of
ATA reflect the severity of skin sclerosis in patients with SSc (14).
The levels of anti-RNAP III antibodies were analyzed in two
longitudinal studies but the clinical usefulness of their quantitative
measurement remains unclear (16, 17). First, anti-RNAP III levels
were measured by ELISA in more than 500 SSc patients although
serial evaluation was performed in only six anti-RNAP III positive
SSc patients (16). In four patients, the anti-RNAP III antibody
level increased early in the disease course and then decreased, cor-
relating closely with the modified Rodnan skin thickness score.
Two patients developed renal crisis following rapid increases in
the anti-RNAP III levels (16). In a second study of 64 SSc patients,
there was no association between changes in anti-RNAP III lev-
els and organ complications, but there was a weak but significant
correlation between change in modified Rodnan skin score and
anti-RNAP III levels (17).
Because of the limited data available, larger, multi-center,
prospective studies are needed to evaluate the relevance of serial
measurements of autoantibodies in SSc patients.
ARE SSc AUTOANTIBODIES MUTUALLY EXCLUSIVE?
As discussed above, with the exception of Ro52/TRIM21 autoanti-
bodies, the most common autoantibodies observed in SSc sera
are considered to be mutually exclusive. However, with the
more recent advent of multiplexed immunoassays, such as LIA,
ALBIA, and now, the chemiluminescent immunoassay (CIA), this
perspective is changing (2).
In several studies using IIF, immunoprecipitation, and immun-
odiffusion, only a very small proportion of SSc sera were found
to have more than one SSc-related antibody (18, 19). In a study
of 180 SSc patients using IIF, immunodiffusion, and immunoblot
for the detection of ATA and ACA, coexisting ACA and ATA anti-
bodies were found in 10 sera by all three methods. These patients
presented heterogeneous clinical manifestations and 6 of the 10
patients had dcSSc (18). More recently, the coexistence of CENP
autoantibodies and ATA was analyzed in 4,687 patients from the
EUSTAR database. Twenty-nine patients (0.6%) were documented
double-positive for both ATA and ACA. Sera of 14 patients were
available for central reanalysis by IIF, enzyme immunoassay, and
immunoblot to confirm antibody status, of which eight were
confirmed to contain both autoantibodies. The prevalence of cuta-
neous and visceral manifestations in double-positive patients was
similar in comparison to ATA single-positive patients (19).
However, in a recent analysis of 528 SSc sera from the Australian
Scleroderma Interest Group (ASIG) in which 16 autoantibodies
were detected by LIA, the presence of monospecific autoantibod-
ies was surprisingly less common than the detection of multiple
antibodies. For example, anti-CENP was associated with other
autoantibodies in 60% of positive sera, anti-Ro-52/TRIM21 in
94%, and ATA in 39% of sera (2).
In an Italian cohort of 210 SSc patients in which a commercially
available LIA for the simultaneous detection of 13 SSc-associated
autoantibodies was used, with the exception of anti-Ro52/TRIM21
(specificity of 50%), all the autoantibodies were very specific
(from 93.3% of anti-PMScl-75 to 100% of anti-PDGFR, AFA, and
anti-RP-11) for SSc (5). Excluding anti-Ro52/TRIM21 from the
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evaluation because it was considered not specific for SSc, anti-
PMScl-75 was associated with ACA in seven sera, with other
autoantibodies in seven additional sera, and antibodies directed
to both PMScl-75 and PMScl-100 were found in nine patients.
Anti-Ku was associated with another autoantibody in 4 of 10 pos-
itive patients, and anti-PMScl-110 was also found associated with
another autoantibody in 3 of 14 patients (5).
In another recent study in which 13 antibodies were measured
by ALBIA, the simultaneous presence of at least three antibod-
ies was found in only 4% of SSc patients, but the simultaneous
presence of two antibodies was found in 17% of patients (20).
Thus, with an increasing number of diagnostic assays for the
detection of autoantibodies related to SSc and other ARD, the
coexistence of autoantibodies in SSc patients have been more
frequently described although the clinical and pathological sig-
nificance of these findings are still not clear. Moreover, more
diligent attention needs to be given to the standardization of these
immunoassays (5).
ARE AUTOANTIBODIES IN SSc PATHOGENIC?
Activation of the cellular and humoral immune systems has been
clearly implicated in the pathophysiology of SSc. As discussed
above, although the autoantibodies present in SSc sera correlate
with distinct clinical phenotypic subsets, as well as disease severity,
and the risk of specific organ complications, their pathogenic rele-
vance is still unclear. Because the vast majority of SSc autoantigens
described to date are apparently intracellularly sequestered and
presumably not accessible to circulating autoantibodies, there are
controversies about how these autoantibodies could bind to their
cognate autoantigens, and cause cell damage or related disease
features (21).
Nonetheless, an intriguing pathogenic role, especially for ATA,
has been suggested by some studies (21, 22). In particular, purified
ATA from SSc sera were found to bind directly to the cell surface
of fibroblasts, a plausible cellular target in SSc pathogenesis (22).
In another study, the same group reported that the binding of ATA
to fibroblasts could subsequently stimulate adhesion and activa-
tion of monocytes in vitro (23). Although these findings do not
necessarily implicate ATA in the pathogenesis of the disease, it is
an intriguing link to increased immune responses and fibrosis in
SSc (6).
More recently, autoantibodies directed against non-nuclear
autoantigens described in SSc were recognized as having poten-
tially pathogenic roles in vascular damage and tissue fibrosis in SSc
(2). They include antibodies directed to endothelial cells, fibrillin-
1, fibroblasts, against matrix metalloproteinases (MMP), such
as MMP-1 (interstitial collagenase) and MMP-3 (stromelysin),
and more recently, the PDGF receptor, the angiotensin II type
1 receptor (AT1R), and ETAR (Table 2) (2, 5, 6, 24).
Anti-fibroblast antibodies have been shown to be present in up
to 58% of SSc patients and induce fibroblast activation in vitro
(25). In another study, fibroblasts stimulated with fibroblast anti-
bodies showed an increased capacity to degrade collagen matrix
and produce MMP-1 while the production of total collagen, type
I collagen, and tissue inhibitor of metalloproteinase-1 (TIMP-1)
was unaffected (26).
Table 2 | Pathogenic autoantibodies in systemic sclerosis (SSc).
% Frequency
in SSc
Pathogenic roles in SSc
Anti-fibroblast 26–58 Induce fibroblast activation
in vitro
Anti-fibrillin-1 >50 Activate fibroblasts in vitro




(MMP) -1 and -3
49–52 Inhibit MMP collagenase activity
Reduce of ECM turnover
Anti-endothelial cells 44–84 Activation of endothelial cells
apoptosis in vitro
Anti-PDGF receptor 33–100 Activation of the PDGF receptor
Stimulation of reactive oxygen
species and collagen production,






82–83 Stimulation of the production of
ROS and collagen by fibroblasts
ECM, extracellular matrix; MMP, matrix metalloproteinase; PDGF, platelet derived
growth factor; TGF, transforming growth factor.
Anti-fibrillin-1 antibodies have been reported in >50% of
SSc patients and activate fibroblasts and stimulate release of
TGF-β (24). Anti-fibrillin-1 antibodies have shown to acti-
vate normal fibroblasts in vitro, resulting in increased produc-
tion of collagens and other extracellular matrix (ECM) com-
ponents characteristically overexpressed in SSc fibroblasts (6).
Neutralization of TGF-β with anti-TGF-β antibodies significantly
decreased the activation of fibroblasts by anti-fibrillin-1 anti-
bodies. Nonetheless, their pathogenic role remains uncertain as
another study, which evaluated autoantibodies against “properly”
folded fibrillin-1, did not find these autoantibodies in sera from
SSc patients (27).
Antibodies to MMP-1 and MMP-3 reported in the sera of SSc
patients were considered to be specific for SSc and were pro-
posed to prevent the degradation of excessive collagen and ECM
components in SSc (6, 24).
Anti-endothelial cells antibodies were reported in 44–84% of
SSc patients (24) and were associated with more severe vascu-
lar involvement. AECA from SSc patients have been reported to
induce EC activation and apoptosis in vitro and to induce the cas-
pase 3 apoptotic pathway by both ATA and CENP positive SSc
sera (28). Moreover, increased gene expression of fibrillin-1 was
observed in human dermal endothelial cells stimulated with SSc
sera. Immunohistochemistry studies of human dermal endothelial
cells also demonstrated the aberrant expression of fibrillin-1 pro-
tein in apoptotic endothelial cells treated with SSc sera containing
AECAs (28).
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A bioassay consisting of embryonic fibroblasts with or without
PDGFR subunits detected anti-PDGF receptor antibodies in 100%
of SSc patients (29). IgG autoantibodies from SSc were found
to activate the human PDGF receptor and induce the Ha-Ras-
ERK1/2 pathways and reactive oxygen species (ROS), which stim-
ulated type I collagen-gene expression and also converted resting
fibroblasts into activated myofibroblasts. In addition, autoanti-
body activity was abolished in control experiments after prein-
cubation of immunoglobulins with recombinant PDGF receptor
and preincubation of mouse embryonic fibroblasts with PDGF
receptor tyrosine kinase inhibitors, suggesting that anti-PDGF
receptor antibodies could be potentially pathogenic (29). How-
ever, the specificity of anti-PDGF antibodies is uncertain as they
were also detected in chronic graft-versus-host disease and in
healthy sera (2). More recently, agonist activity of PDGF recep-
tor was not detected in SSc sera (2). While these studies show great
promise in an understanding of the pathogenesis of SSc, the preva-
lence, specificity, and the role of these autoantibodies remain to be
confirmed (6).
Autoantibodies directed against AT1R and ETAR were identi-
fied in most SSc sera and were associated with pulmonary fibrosis,
PAH, and with higher mortality (7). Anti-AT1R and anti-ETAR
antibodies specifically bound to their respective receptors on
endothelial cells, and were shown to induce extracellular signal-
regulated kinase phosphorylation, and to increase TGF-β gene
expression in endothelial cells, suggesting a possible involvement
in fibrosis (7). Interestingly, the same group recently reported acti-
vation of human microvascular endothelial cells (HMEC-1) via
anti-AT1R and anti-ETAR antibody-positive IgG from SSc sera
(30). The mRNA levels of the pro-inflammatory interleukin-8
(IL-8) and of the vascular cell adhesion molecule-1 (VCAM-
1) were increased in HMEC-1 after exposure to anti-AT1R and
anti-ETAR antibody-positive IgG from SSc patients (SSc-IgG).
Exposure of HMEC-1 to SSc-IgG increased neutrophil migra-
tion through endothelial cells and activation of ROS. Human
fibroblasts showed increased expression of type I collagen after
treatment with anti-AT1R and anti-ETAR antibody-positive SSc-
IgG. Increased neutrophil counts in bronchoalveolar lavage fluids
and structural abnormalities of the lungs of naive mice were
also detected after treatment with anti-AT1R and anti-ETAR
antibody-positive SSc-IgG (30).
Finally, a study using cDNA microarrays to evaluate gene
expression in SSc dermal fibroblasts demonstrated that several
autoantigen genes specifically targeted in SSc (fibrillarin, cen-
tromere protein B, centromere autoantigen P27, and RNA poly-
merase II) were overexpressed. Quantitative RT-PCR confirmed
overexpression of these autoantigens and also revealed increased
levels of ATA transcripts in SSc fibroblasts (31).
CONCLUDING REMARKS
In summary, serum autoantibodies are considered important bio-
markers for the early and accurate diagnosis of SSc, and are
associated with distinctive clinical subsets and different prog-
nostic features. Although SSc-related autoantibodies were histor-
ically considered to be mutually exclusive and remain stable over
the course of the disease, in recent studies using more sensitive
immunoassays a more frequent coexistence of autoantibodies
in SSc patients than previously appreciated has been reported.
Finally, some autoantibodies directed against certain autoanti-
gen targets have been shown to induce inflammation, to activate
fibroblasts, to favoring collagen synthesis and deposition, and to
activate endothelial cells thereby participating in the pathogen-
esis of SSc. The elucidation of the pathogenic role of autoan-
tibodies in SSc may identify new therapeutic targets for this
challenged disease.
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